Robert Balfour
Vorstandsvorsitzender bei Promatix, Inc.
Profil
Robert Balfour is currently the Chief Executive Officer at Promatix, Inc. and an Investment Director at Alsa Management Services Ltd.
He holds a doctorate degree from Imperial College London and an undergraduate degree from Southampton Business School.
Aktive Positionen von Robert Balfour
Unternehmen | Position | Beginn |
---|---|---|
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 01.07.2018 |
Promatix, Inc.
Promatix, Inc. Data Processing ServicesTechnology Services Promatix, Inc. is based in London, UK. The British company takes a data-driven approach by utilizing a confluence of multi-omic datasets and proprietary algorithms. Promatix, Inc. is a company that was founded to accelerate the process of novel target and drug discovery for cancer patients. The company was founded in 2020, and Robert Balfour has been the CEO of the company since 2021. | Vorstandsvorsitzender | 01.03.2021 |
Ausbildung von Robert Balfour
Imperial College London | Doctorate Degree |
Southampton Business School | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Alsa Management Services Ltd
Alsa Management Services Ltd Investment ManagersFinance Alsa Management Services Ltd (ALSA Ventures) is a venture capital firm founded in 2018. The firm is headquartered in London, United Kingdom. | Finance |
Promatix, Inc.
Promatix, Inc. Data Processing ServicesTechnology Services Promatix, Inc. is based in London, UK. The British company takes a data-driven approach by utilizing a confluence of multi-omic datasets and proprietary algorithms. Promatix, Inc. is a company that was founded to accelerate the process of novel target and drug discovery for cancer patients. The company was founded in 2020, and Robert Balfour has been the CEO of the company since 2021. | Technology Services |